Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio is a promising investment opportunity as the company is at a pivotal point in multiple clinical trials for potential therapies. With projected revenue from Jemperli and promising results from imsidolimab, the company has the potential for significant revenue growth in the near future. However, investors should also consider potential risks such as ongoing litigation and financial obligations.

Bears say

AnaptysBio is a clinical-stage biotechnology company with a narrow product portfolio focused on developing immune cell modulating antibodies for inflammatory and oncology indications. While the company has potential near-term catalysts such as the potential approval of Jemperli in locally advanced rectal cancer, the opportunity is smaller than their existing endometrial cancer franchise. The company also faces ongoing litigation and regulatory risks that could impede its future success.

AnaptysBio (ANAB) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 11 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.